| John P Boehmer, MD | |
|
500 University Dr, Hershey, PA 17033-2360 | |
| (800) 243-1455 | |
| Not Available |
| Full Name | John P Boehmer |
|---|---|
| Gender | Male |
| Speciality | Advanced Heart Failure And Transplant Cardiology |
| Experience | 38 Years |
| Location | 500 University Dr, Hershey, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053369645 | NPI | - | NPPES |
| 0012890300001 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Good Samaritan Hospital | Lebanon, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Milton S Hershey Medical Center Physicians Group | 3870405483 | 1400 |
News Archive
The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).
Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.
A new study from the Bradley Hasbro Children's Research Center has found that family-based cognitive behavioral therapy (CBT) is beneficial to young children between the ages of five and eight with Obsessive-Compulsive Disorder (OCD).
There is strong epidemiological evidence of the importance of regular physical activity, such as brisk walking and jogging, in the management and rehabilitation of cardiovascular disease and in lowering the risk of death from other diseases such as hypertension, stroke, and type 2 diabetes.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
› Verified 6 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).
Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.
A new study from the Bradley Hasbro Children's Research Center has found that family-based cognitive behavioral therapy (CBT) is beneficial to young children between the ages of five and eight with Obsessive-Compulsive Disorder (OCD).
There is strong epidemiological evidence of the importance of regular physical activity, such as brisk walking and jogging, in the management and rehabilitation of cardiovascular disease and in lowering the risk of death from other diseases such as hypertension, stroke, and type 2 diabetes.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John P Boehmer, MD Po Box 858, Mc A410, Hershey, PA 17033-0858 Ph: (800) 243-1455 | John P Boehmer, MD 500 University Dr, Hershey, PA 17033-2360 Ph: (800) 243-1455 |
News Archive
The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).
Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.
A new study from the Bradley Hasbro Children's Research Center has found that family-based cognitive behavioral therapy (CBT) is beneficial to young children between the ages of five and eight with Obsessive-Compulsive Disorder (OCD).
There is strong epidemiological evidence of the importance of regular physical activity, such as brisk walking and jogging, in the management and rehabilitation of cardiovascular disease and in lowering the risk of death from other diseases such as hypertension, stroke, and type 2 diabetes.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
› Verified 6 days ago
Nicole Swallow, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, H088, Hershey, PA 17033 Phone: 717-531-1692 | |
Karen Louise Krok, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 Fax: 717-531-0061 | |
James O Ballard, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-233-4082 | |
Poonam Na Bai, Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-6585 | |
Wilbert Hoffman Beachy Iv, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-7300 | |
Samer Nabil Muallem, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 | |
Dr. Robert David Aronoff, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 |